Abstract
Multiple sclerosis (MS) is an inflammatory demyelinating disorder of the central nervous system (CNS). Natalizumab (®Tysabri) is a humanized recombinant monoclonal antibody that binds to the alpha (α)4 chain of the α4 beta (β)1 integrin (very late activation antigen 4; VLA-4), and α4β7 integrin. Recently, two patients with MS and one patient with Crohn's disease who were treated with natalizumab in the setting of clinical trials developed progressive multifocal leukoencephalopathy (PML), an opportunistic infection of the brain with the polyoma virus JC. We recently showed that natalizumab decreases the numbers of CD4+ and CD8+ T lymphocytes, CD19+ B cells, and CD138+ plasma cells in the cerebrospinal fluid (CSF) of patients with MS on natalizumab therapy. In addition, we demonstrated that the cell numbers in CSF remained unchanged even 6 months after cessation of natalizumab treatment.
Original language | English (US) |
---|---|
Pages (from-to) | 39-41 |
Number of pages | 3 |
Journal | Journal of the Neurological Sciences |
Volume | 274 |
Issue number | 1-2 |
DOIs | |
State | Published - Nov 15 2008 |
Keywords
- Antigen presentation
- Brain
- Crohn's disease
- Immunosuppression
- Inflammatory bowel disease
- Integrin
- JC virus
- Natalizumab
- PML
- Perivascular spaces
- Pharmacotherapy
- Polyoma virus
- Progressive multifocal leukoencephalopathy
- Tysabri
- Virchow Robin space
ASJC Scopus subject areas
- Neurology
- Clinical Neurology